Core Viewpoint - The inclusion of Naxitamab in the commercial insurance directory is a significant advancement for children suffering from rare diseases, showcasing the successful implementation of the Boao Lecheng policy by Guangzhou Pharmaceutical Morning Fei [3]. Group 1: Company Achievements - Guangzhou Pharmaceutical Morning Fei has successfully introduced nearly 30 innovative imported drugs and medical devices, most of which have been transformed for domestic use, bridging international products with local healthcare needs [4]. - The company has facilitated early access to Naxitamab, allowing patients to receive the drug 18 months ahead of its official domestic launch, with prices being only one-seventh of those in the United States [3][4]. Group 2: Policy Impact - The Boao Lecheng pilot policy has created a green channel for patients in China, enabling early and cost-effective access to foreign medications, particularly for rare diseases, which are a national focus due to their high development costs and pricing [4]. - The support from national commercial insurance significantly reduces the financial burden on families, making essential medications more affordable [4]. Group 3: Future Plans - The company plans to leverage zero tariffs and streamlined administrative processes under the free trade port policy to expand the introduction of quality drugs and medical devices, aiming to provide affordable medications for more patients with rare and severe diseases without the need to go abroad [5].
省政协委员蔡剑秋：让更多罕见病、重症患者享平价好药